Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

MK-8591 With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)
A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral Activity, and Pharmacokinetics of MK-8591 Given in Combination With Doravirine (DOR) and Lamivudine (3TC) in HIV-1-Infected Treatment-Naïve Adults
Status: Enrolling
Updated:  4/25/2018
Whitman Walker Clinic
mi
from
Washington,
MK-8591 With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)
A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral Activity, and Pharmacokinetics of MK-8591 Given in Combination With Doravirine (DOR) and Lamivudine (3TC) in HIV-1-Infected Treatment-Naïve Adults
Status: Enrolling
Updated: 4/25/2018
Whitman Walker Clinic
mi
from
Washington,
Click here to add this to my saved trials
MK-8591 With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)
A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral Activity, and Pharmacokinetics of MK-8591 Given in Combination With Doravirine (DOR) and Lamivudine (3TC) in HIV-1-Infected Treatment-Naïve Adults
Status: Enrolling
Updated:  4/25/2018
Orlando Immunology Center (OIC) ( Site 0105)
mi
from
Orlando, FL
MK-8591 With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)
A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral Activity, and Pharmacokinetics of MK-8591 Given in Combination With Doravirine (DOR) and Lamivudine (3TC) in HIV-1-Infected Treatment-Naïve Adults
Status: Enrolling
Updated: 4/25/2018
Orlando Immunology Center (OIC) ( Site 0105)
mi
from
Orlando, FL
Click here to add this to my saved trials
MK-8591 With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)
A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral Activity, and Pharmacokinetics of MK-8591 Given in Combination With Doravirine (DOR) and Lamivudine (3TC) in HIV-1-Infected Treatment-Naïve Adults
Status: Enrolling
Updated:  4/25/2018
Clinica Arauco Salud ( Site 0200)
mi
from
Santiago,
MK-8591 With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)
A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral Activity, and Pharmacokinetics of MK-8591 Given in Combination With Doravirine (DOR) and Lamivudine (3TC) in HIV-1-Infected Treatment-Naïve Adults
Status: Enrolling
Updated: 4/25/2018
Clinica Arauco Salud ( Site 0200)
mi
from
Santiago,
Click here to add this to my saved trials
MK-8591 With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)
A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral Activity, and Pharmacokinetics of MK-8591 Given in Combination With Doravirine (DOR) and Lamivudine (3TC) in HIV-1-Infected Treatment-Naïve Adults
Status: Enrolling
Updated:  4/25/2018
The Crofoot Research Center, Inc. ( Site 0118)
mi
from
Houston, TX
MK-8591 With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)
A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral Activity, and Pharmacokinetics of MK-8591 Given in Combination With Doravirine (DOR) and Lamivudine (3TC) in HIV-1-Infected Treatment-Naïve Adults
Status: Enrolling
Updated: 4/25/2018
The Crofoot Research Center, Inc. ( Site 0118)
mi
from
Houston, TX
Click here to add this to my saved trials
MK-8591 With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)
A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral Activity, and Pharmacokinetics of MK-8591 Given in Combination With Doravirine (DOR) and Lamivudine (3TC) in HIV-1-Infected Treatment-Naïve Adults
Status: Enrolling
Updated:  4/25/2018
University of California-Davis
mi
from
Sacramento, CA
MK-8591 With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)
A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral Activity, and Pharmacokinetics of MK-8591 Given in Combination With Doravirine (DOR) and Lamivudine (3TC) in HIV-1-Infected Treatment-Naïve Adults
Status: Enrolling
Updated: 4/25/2018
University of California-Davis
mi
from
Sacramento, CA
Click here to add this to my saved trials
MK-8591 With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)
A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral Activity, and Pharmacokinetics of MK-8591 Given in Combination With Doravirine (DOR) and Lamivudine (3TC) in HIV-1-Infected Treatment-Naïve Adults
Status: Enrolling
Updated:  4/25/2018
Tarrant County Infectious Disease Associates
mi
from
Fort Worth, TX
MK-8591 With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)
A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral Activity, and Pharmacokinetics of MK-8591 Given in Combination With Doravirine (DOR) and Lamivudine (3TC) in HIV-1-Infected Treatment-Naïve Adults
Status: Enrolling
Updated: 4/25/2018
Tarrant County Infectious Disease Associates
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Comparison of Adherence Rates to Ritonavir and Its Accompanying Protease Inhibitor
A Comparison of Adherence Rates to Ritonavir (Soft-gel Capsules) and Its Accompanying Protease Inhibitor (PI) in Patients Receiving Ritonavir Boosted PI Regimens
Status: Enrolling
Updated:  4/25/2018
Montefiore Medical Center
mi
from
Bronx, NY
A Comparison of Adherence Rates to Ritonavir and Its Accompanying Protease Inhibitor
A Comparison of Adherence Rates to Ritonavir (Soft-gel Capsules) and Its Accompanying Protease Inhibitor (PI) in Patients Receiving Ritonavir Boosted PI Regimens
Status: Enrolling
Updated: 4/25/2018
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
A Trial to Determine the Long-term Durability of Virologic Suppression in Kaletra Recipients With Imperfect Adherence
A Trial to Determine the Long-term Durability of Virologic Suppression in Kaletra Recipients With Imperfect Adherence
Status: Enrolling
Updated:  4/25/2018
Montefiore Medical Center
mi
from
Bronx, NY
A Trial to Determine the Long-term Durability of Virologic Suppression in Kaletra Recipients With Imperfect Adherence
A Trial to Determine the Long-term Durability of Virologic Suppression in Kaletra Recipients With Imperfect Adherence
Status: Enrolling
Updated: 4/25/2018
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
American Indian and Alaska Native Men Who Have Sex With Men HIV & Substance Abuse Research
American Indian and Alaska Native Men Who Have Sex With Men HIV & Substance Abuse Research
Status: Enrolling
Updated:  4/27/2018
Univ of Washington
mi
from
Seattle, WA
American Indian and Alaska Native Men Who Have Sex With Men HIV & Substance Abuse Research
American Indian and Alaska Native Men Who Have Sex With Men HIV & Substance Abuse Research
Status: Enrolling
Updated: 4/27/2018
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
PHAT Life: Preventing HIV/AIDS Among Teens in Juvenile Justice
PHAT Life: Preventing HIV/AIDS Among Teens in Juvenile Justice
Status: Enrolling
Updated:  4/30/2018
University of Illinois at Chicago
mi
from
Chicago, IL
PHAT Life: Preventing HIV/AIDS Among Teens in Juvenile Justice
PHAT Life: Preventing HIV/AIDS Among Teens in Juvenile Justice
Status: Enrolling
Updated: 4/30/2018
University of Illinois at Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Women's Interagency HIV Study (WIHS)
Women's Interagency HIV Study (WIHS)
Status: Enrolling
Updated:  5/1/2018
University of California at San Francisco
mi
from
San Francisco, CA
Women's Interagency HIV Study (WIHS)
Women's Interagency HIV Study (WIHS)
Status: Enrolling
Updated: 5/1/2018
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Women's Interagency HIV Study (WIHS)
Women's Interagency HIV Study (WIHS)
Status: Enrolling
Updated:  5/1/2018
Georgetown University Medical Center
mi
from
Washington,
Women's Interagency HIV Study (WIHS)
Women's Interagency HIV Study (WIHS)
Status: Enrolling
Updated: 5/1/2018
Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Women's Interagency HIV Study (WIHS)
Women's Interagency HIV Study (WIHS)
Status: Enrolling
Updated:  5/1/2018
Chicago Consortium
mi
from
Chicago, IL
Women's Interagency HIV Study (WIHS)
Women's Interagency HIV Study (WIHS)
Status: Enrolling
Updated: 5/1/2018
Chicago Consortium
mi
from
Chicago, IL
Click here to add this to my saved trials
Women's Interagency HIV Study (WIHS)
Women's Interagency HIV Study (WIHS)
Status: Enrolling
Updated:  5/1/2018
Montefiore Medical Center
mi
from
Bronx, NY
Women's Interagency HIV Study (WIHS)
Women's Interagency HIV Study (WIHS)
Status: Enrolling
Updated: 5/1/2018
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Women's Interagency HIV Study (WIHS)
Women's Interagency HIV Study (WIHS)
Status: Enrolling
Updated:  5/1/2018
SUNY / Health Sciences Ctr at Brooklyn
mi
from
Brooklyn, NY
Women's Interagency HIV Study (WIHS)
Women's Interagency HIV Study (WIHS)
Status: Enrolling
Updated: 5/1/2018
SUNY / Health Sciences Ctr at Brooklyn
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Multicenter AIDS Cohort Study (MACS)
Multicenter AIDS Cohort Study (MACS)
Status: Enrolling
Updated:  5/1/2018
Public Health Center
mi
from
Los Angeles, CA
Multicenter AIDS Cohort Study (MACS)
Multicenter AIDS Cohort Study (MACS)
Status: Enrolling
Updated: 5/1/2018
Public Health Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Multicenter AIDS Cohort Study (MACS)
Multicenter AIDS Cohort Study (MACS)
Status: Enrolling
Updated:  5/1/2018
CORE Health Center
mi
from
Chicago, IL
Multicenter AIDS Cohort Study (MACS)
Multicenter AIDS Cohort Study (MACS)
Status: Enrolling
Updated: 5/1/2018
CORE Health Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Multicenter AIDS Cohort Study (MACS)
Multicenter AIDS Cohort Study (MACS)
Status: Enrolling
Updated:  5/1/2018
Johns Hopkins School of Public Health
mi
from
Baltimore, MD
Multicenter AIDS Cohort Study (MACS)
Multicenter AIDS Cohort Study (MACS)
Status: Enrolling
Updated: 5/1/2018
Johns Hopkins School of Public Health
mi
from
Baltimore, MD
Click here to add this to my saved trials
Multicenter AIDS Cohort Study (MACS)
Multicenter AIDS Cohort Study (MACS)
Status: Enrolling
Updated:  5/1/2018
University of Pittsburgh School of Public Health
mi
from
Pittsburgh, PA
Multicenter AIDS Cohort Study (MACS)
Multicenter AIDS Cohort Study (MACS)
Status: Enrolling
Updated: 5/1/2018
University of Pittsburgh School of Public Health
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Pharmacokinetics and Pharmacodynamics of DMPA With HIV PrEP
The Pharmacokinetic and Pharmacodynamic Impacts of Depot Medroxyprogesterone Acetate on HIV Pre-exposure Prophylaxis (PrEP)
Status: Enrolling
Updated:  5/2/2018
Magee-Womens Hospital of UPMC
mi
from
Pittsburgh, PA
Pharmacokinetics and Pharmacodynamics of DMPA With HIV PrEP
The Pharmacokinetic and Pharmacodynamic Impacts of Depot Medroxyprogesterone Acetate on HIV Pre-exposure Prophylaxis (PrEP)
Status: Enrolling
Updated: 5/2/2018
Magee-Womens Hospital of UPMC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials